Summary:
- Theratechnologies Inc. (THTX, Financial) jumps 36% following its acquisition announcement by CB Biotechnology.
- Analysts predict a potential upside of 23.82% with a price target of $3.90.
- GuruFocus estimates suggest a downside risk of 48.89% based on GF Value.
Theratechnologies (THTX) shares witnessed a remarkable surge of 36% post-announcement of its acquisition by CB Biotechnology, a subsidiary of Future Pak, valued at $254 million. The deal includes $3.01 per share with an additional contingent value right per share that could raise the total by $1.19 per share. This acquisition represents a significant premium over the previous Nasdaq closing prices, underlining investor confidence.
Wall Street Analysts' Predictions
Analyst insights indicate a positive outlook for Theratechnologies Inc (THTX, Financial). With price targets from two analysts, the average target price is set at $3.90. The high estimate reaches $4.00, while the low estimate is $3.80. This suggests a promising upside of 23.82% from the current price of $3.15. For those seeking more detailed information, visit the Theratechnologies Inc (THTX) Forecast page.
The average brokerage recommendation for Theratechnologies Inc (THTX, Financial) stands at 2.0, indicating an "Outperform" status according to two brokerage firms. This rating uses a scale from 1 to 5, where 1 denotes a Strong Buy and 5 indicates a Sell.
GuruFocus Valuation Analysis
According to GuruFocus estimates, the projected GF Value for Theratechnologies Inc (THTX, Financial) in the upcoming year is $1.61. This valuation suggests a potential downside of 48.89% from the current price of $3.1498. The GF Value is GuruFocus' assessment of the fair trading value of a stock, calculated by considering the stock's historical trading multiples, past business growth, and anticipated future business performance. For a comprehensive analysis, visit the Theratechnologies Inc (THTX) Summary page.
